

02 Oct 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer's; other Alzheimer's players rise after the lecanemab results; Leqvio's importance to Novartis; Pfizer's secret sauce for digitalization; and Amgen's clinical trial diversity efforts.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 30 September 2022, including: landmark results for lecanemab in Alzheimer's; other Alzheimer's players rise after lecanemab results; Leqvio's importance to [Novartis AG](#); [Pfizer Inc.](#)'s secret sauce for digitization; and [Amgen, Inc.](#)'s clinical trial diversity initiatives.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Banner Moment For Alzheimer's Positions Eisai/Biogen At The Head Of The Pack](#)" - Scrip, 27 Sep, 2022.)

(Also see "[Rising Tide Lifts Many Ships In Wake Of Eisai/Biogen's Lecanemab Readout](#)" - Scrip, 28 Sep, 2022.)

(Also see "[Leqvio Launch Will Be Fundamental To Success Of New Novartis](#)" - Scrip, 23 Sep, 2022.)

(Also see "[Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times](#)" - Scrip, 28

Sep, 2022.)

(Also see "[*Amgen VP Encouraged By Initial Clinical Trial Diversity Efforts*](#)" - Scrip, 26 Sep, 2022.)

[*Click here to explore this interactive content online*](#) 